Women with advanced breast cancer who progress on prior CDK4/6 inhibition can still benefit from second-line treatment with a CDK4/6 inhibitor as part of combination therapy.

Researchers from USask have identified a potential target for eliminating breast cancer cells. The team was led by Dr. Franco ...

Efti plus Keytruda and chemo achieved a 61% response rate in first-line advanced non-squamous non–small cell lung cancer, ...

Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in ...

Sr. Ann courageously shares her journey — from the moment of diagnosis to the treatments, emotional battles, and the unwavering faith and support that have fueled her recovery.

England’s drug approval body has resisted pressure from pharmaceutical companies to loosen its process for recommending drugs and is pressing instead for the NHS to speed up the rollout of approved ...

Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when ...

Zongertinib conferred a clinically meaningful benefit in patients with previously treated, advanced, HER2-mutant NSCLC in a phase 1 trial.

Swiss pharmaceutical company Roche has reported final overall survival outcomes from a long-term Phase III trial of Perjeta ...

CNN anchor and breast cancer patient Sara Sidner, Dr. Vinod Balachandran, and Novartis U.S. president Victor Bulto discussed ...

T-DXd followed by THP improved pCR in high-risk, early-stage HER2+ breast cancer in the phase 3 DESTINY-Breast11 trial.

Roche’s Herceptin and Perjeta duo is already part of a well-established standard of care in early-stage HER2-positive breast ...